Sabine Hachem-Khalife

Villejuif, 94805, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients.

Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients.

Journal: Blood cancer journal
Published: January 21, 2025

Venetoclax-proteasome inhibitor-dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm.

Venetoclax-proteasome inhibitor-dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm.

Journal: Blood advances
Published: August 20, 2024

Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO's pharmacovigilance database.

Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO's pharmacovigilance database.

Journal: Blood cancer journal
Published: July 30, 2024

When monoclonal gammopathy-associated chronic neutrophilic leukemia is a reactive process distinct from a clonal myeloproliferative neoplasm: Lessons from mistakes.

When monoclonal gammopathy-associated chronic neutrophilic leukemia is a reactive process distinct from a clonal myeloproliferative neoplasm: Lessons from mistakes.

Journal: EJHaem
Published: March 21, 2023

Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers.

Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers.

Journal: HemaSphere
Published: May 03, 2021

Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights.

Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 29, 2021

ATG2B/GSKIP in de novo acute myeloid leukemia (AML): high prevalence of germline predisposition in French West Indies.

ATG2B/GSKIP in de novo acute myeloid leukemia (AML): high prevalence of germline predisposition in French West Indies.

Journal: Leukemia & lymphoma
Published: February 08, 2021

Spontaneous molecular response of IDH2 acute myeloid leukemia.

Spontaneous molecular response of IDH2 acute myeloid leukemia.

Journal: Annals of hematology
Published: July 02, 2019

Germline RUNX1 Intragenic Deletion: Implications for Accurate Diagnosis of FPD/AML.

Germline RUNX1 Intragenic Deletion: Implications for Accurate Diagnosis of FPD/AML.

Journal: HemaSphere
Published: January 30, 2019

ANTIBIOSTOP, for all?

ANTIBIOSTOP, for all?

Journal: Infectious diseases (London, England)
Published: February 20, 2018
Showing 1-10 of 10

Last Updated: 09/26/2026